Particle beam and immune therapy join forces against cervical cancer

NCT ID NCT07702838

Recruiting now Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates a new treatment approach for locally advanced cervical cancer that combines carbon ion radiotherapy with immunotherapy (anti-PD-1) and chemotherapy. The goal is to see if this triple therapy improves how long patients live without their cancer progressing. The trial enrolls 30 women with stage IIB-IVA cervical cancer who will receive the combination treatment and be followed for outcomes like survival and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carbon ion radiotherapy plus anti-PD-1 immunotherapy and chemotherapy (cisplatin or carboplatin)
What this could lead to: If successful, this combination could offer a more effective treatment option for locally advanced cervical cancer, potentially improving survival rates.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply broadly. The combination therapy also carries risks of side effects from radiation, immunotherapy, and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE CERVICAL NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.